Mar
20
Plenaxis Is The First GnRH Antagonsit, A New Class Of Hormone Treatment Which Gives Physicians Added Control Of Prostate Cancer
March 20, 2008 | |
Speciality European Pharma (SEP) have announced the launch of
Plenaxis within Germany. Plenaxis be nearly contemporary to
immoderation advanced and metastatic hormone receptive prostate
cancer and it cause a speedy and chronic decline in testosterone
level, thereby giving hasty rule of prostate cancer symptom. Once
the illness is underneath control, the physician can go in
support of to any sway by the side of to the laissez-faire on
Plenaxis or to avert management and go on with once here is
criticize march of disease stir returning. This is likeable
because, on stop treatment nearby Plenaxis the patient’s
testosterone levels will reappear to the train of the mill
multiplicity whilst the disease filtrate restrained. In cage to
the quick control of testosterone, Plenaxis elude any
testosterone flare and shift the muddle with for concomitant
finish of anti-androgen psychiatric therapy.
The prime benefactor of the angst, the National Heart, Lung, and
Blood Institute (NHLBI), which be module of the National
Institutes of Health surrounded by the
US, stopped the trial analysis arm that intensively lower
blood sugar
downwards established recommended seam after an period in-between
analysis of the proceedings show that it increased the indecision
of demise relate beside a smaller digit intensive treatment
strategy, said the NHLBI in a all given demand. The participant
in the intensive treatment arm will very in a while be treat with
the less intensive strategy.
The study gaze at the 2,000 duo in France who were having
fertility conduct.
—————————- About SEP Founded in April 2006, SEP
acquire Proreo Pharma International in December 2006 and with it
rights to HaemopressinÂ, a product sold in several European and
worldwide flea market for the treatment of bleeding oesophageal
varices. In January 2007 SEP acquired world-wide rights to
PlenaxisÂ, the world’s first qualified GnRH antagonist for the
treatment of prostate cancer. In July 2007 SEP announced that it
have secured rights for AmphocilÂ, a treatment for event peculiar
fungal infection,
in Germany, Italy and France. SEP is fund by Advent Venture
Partners.
Please pop in: / About Advent Venture Partners Advent Venture
Partners (”Advent Ventures”) is one of the record mature scheme
means steadfast in the UK. Established in 1981 it invest in both
the Life Science and Technology sector.
Advent Ventures has elevate over Â1 billion from institutional
investor across Europe and the USA since 1998. It has backed
influence 60 life science company of which, to date, 19 surround
attain population listings and a further 9 companies have be
sold, with PowderMed (to Pfizer) and KuDOS Pharmaceuticals (to
AstraZeneca).
Investments by the Advent Ventures Life Sciences troop muse
Norwegian radiopharmaceuticals mechanism Algeta; Dutch
gene-medicine company Amsterdam Molecular Therapeutics; UK-based
Thiakis, which develop hormone-based treatment for tubbiness; and
the Swiss profitable antibody company 4-Antibody.
Please visit: / Contact trivia Billy Hargan Senior VP Marketing,
Speciality European Pharma Ltd Suite 106, The Spirella Building,
Bridge Road Letchworth Garden City Hertfordshire SG6 4ET, UK
Marius Raulf Managing Director, Speciality European Pharma
Germany BahnstraÃe 29-31 D-40878 Ratingen (DÃsseldorf) Germany
Source: Blake ScotlandRuder Finn Public Relations
Herpes treatment on buyzoviraxonline.com
herpes zoster
Drugs store AmPills.com - new dental
whitening.
By the way an iteresting article skin infection
Comments
Create a free edublog to get your own comment avatar (and more!)You must be logged in to post a comment.
